Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
BIOFILM CONTROL<br />
Biopôle Clermont-Limagne<br />
63360 SAINT-BEAUzIRE - FRANCE<br />
Phone: +33 4 73 33 39 80<br />
Email: pascal.mayer@biofilmcontrol.com<br />
Web site: www.biofilmcontrol.com<br />
Contact: Pascal MAYER<br />
We leverage our unique and proprietary biological assays in order to be the first to<br />
discover compounds for fighting bacterial biofilms involved in triggering and sustaining<br />
severe and common human diseases.<br />
Our initial therapeutic targets are <strong>at</strong>opic derm<strong>at</strong>itis, acne, rhinosinusitis and pressure<br />
ulcers, each addressing a multi-billion Euro market.<br />
Our initial screening campaign with a focus on staphylococci has already identified<br />
a first set of active compounds with a promising chemical p<strong>at</strong>tern which we are now<br />
pushing into hit-to-lead and preclinical processes.<br />
BIO-MODELING SYSTEMS<br />
26 rue Saint Lambert<br />
75015 PARIS - FRANCE<br />
Phone: +33 6 83 06 12 72<br />
Email: manuel.gea@bmsystems.net<br />
Web site: www.bmsystems.net<br />
Contact: Manuel GEA<br />
BMSystems, is the first and to d<strong>at</strong>e the only systems biology company th<strong>at</strong> succeeded<br />
to cre<strong>at</strong>e in-silico heuristic models valid<strong>at</strong>ed in-vivo th<strong>at</strong> led to discoveries, p<strong>at</strong>ents,<br />
or oper<strong>at</strong>ional businesses through its innov<strong>at</strong>ive business model, in the fields of<br />
infectious diseases, neurology, psychi<strong>at</strong>ry, oncology and industrial biotech.<br />
Cre<strong>at</strong>ed in 2004, profitable since 2006, BMSystems is involved in the development its<br />
second spin-off in psychi<strong>at</strong>ric disorders after the success of its first one, Pherecydes-<br />
Pharma, in infectious diseases.<br />
31
Change language